Leveraging an open science drug discovery model to develop CNS penetrant ALK2 inhibitors for the treatment of diffuse intrinsic pontine glioma
There are currently no effective chemotherapeutic drugs approved for the treatment of diffuse intrinsic pontine glioma (DIPG), an aggressive pediatric cancer resident in the pons region of the brainstem. Radiation therapy is beneficial but not curative, with the condition being uniformly fatal. Anal...
Main Authors: | Smil, D, Wong, JF, Williams, E, Adamson, R, Howarth, A, McLeod, D, Mamai, A, Kim, S, Wilson, B, Kiyota, T, Aman, A, Owen, J, Poda, G, Horiuchi, K, Kuznetsova, E, Ma, H, Hamblin, JN, Cramp, S, Roberts, O, Edwards, AM, Uehling, D, Al-awar, R, Bullock, AN, O'Meara, J, Isaac, M |
---|---|
Format: | Journal article |
Language: | English |
Published: |
American Chemical Society
2020
|
Similar Items
-
Targeting ALK2: an open science approach to developing therapeutics for the treatment of diffuse intrinsic pontine glioma
by: Ensan, D, et al.
Published: (2020) -
Discovery of conformationally constrained ALK2 inhibitors
by: González-Álvarez, H, et al.
Published: (2024) -
ALK2 inhibitors display beneficial effects in preclinical models of ACVR1 mutant diffuse intrinsic pontine glioma
by: Carvalho, D, et al.
Published: (2019) -
Effectiveness of ALK inhibitors in treatment of CNS metastases in NSCLC patients
by: Michał Gil, et al.
Published: (2023-12-01) -
Pontine tubercular abscess: A rare presentation of CNS tuberculosis masquerading as glioma in a child
by: Bikash Chandra Adhikari, et al.
Published: (2024-07-01)